These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 18293380)

  • 1. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea.
    Singh SA; Koumbourlis AC; Aygun B
    Pediatr Blood Cancer; 2008 Jun; 50(6):1258-60. PubMed ID: 18293380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment.
    Steinberg MH; Barton F; Castro O; Pegelow CH; Ballas SK; Kutlar A; Orringer E; Bellevue R; Olivieri N; Eckman J; Varma M; Ramirez G; Adler B; Smith W; Carlos T; Ataga K; DeCastro L; Bigelow C; Saunthararajah Y; Telfer M; Vichinsky E; Claster S; Shurin S; Bridges K; Waclawiw M; Bonds D; Terrin M
    JAMA; 2003 Apr; 289(13):1645-51. PubMed ID: 12672732
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hydroxyurea therapy: improving the lives of patients with sickle cell disease.
    Anderson N
    Pediatr Nurs; 2006; 32(6):541-3. PubMed ID: 17256291
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxyurea for the treatment of sickle cell anemia.
    Platt OS
    N Engl J Med; 2008 Mar; 358(13):1362-9. PubMed ID: 18367739
    [No Abstract]   [Full Text] [Related]  

  • 5. Sickle cell patients find a brand New World.
    Noonan SS
    N J Med; 1999 Aug; 96(8):23-5. PubMed ID: 10457727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hydroxyurea use among children with sickle cell anemia.
    Reeves SL; Jary HK; Gondhi JP; Raphael JL; Lisabeth LD; Dombkowski KJ
    Pediatr Blood Cancer; 2019 Jun; 66(6):e27721. PubMed ID: 30900800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Secondary benefit of maintaining normal transcranial Doppler velocities when using hydroxyurea for prevention of severe sickle cell anemia.
    Ghafuri DL; Chaturvedi S; Rodeghier M; Stimpson SJ; McClain B; Byrd J; DeBaun MR
    Pediatr Blood Cancer; 2017 Jul; 64(7):. PubMed ID: 28035747
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of hydroxyurea treatment for patients with hemoglobin SC disease.
    Luchtman-Jones L; Pressel S; Hilliard L; Brown RC; Smith MG; Thompson AA; Lee MT; Rothman J; Rogers ZR; Owen W; Imran H; Thornburg C; Kwiatkowski JL; Aygun B; Nelson S; Roberts C; Gauger C; Piccone C; Kalfa T; Alvarez O; Hassell K; Davis BR; Ware RE
    Am J Hematol; 2016 Feb; 91(2):238-42. PubMed ID: 26615793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxyurea (HU) for prevention of recurrent stroke in sickle cell anemia (SCA).
    Sumoza A; de Bisotti R; Sumoza D; Fairbanks V
    Am J Hematol; 2002 Nov; 71(3):161-5. PubMed ID: 12410569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyurea therapy for sickle cell anemia.
    McGann PT; Ware RE
    Expert Opin Drug Saf; 2015; 14(11):1749-58. PubMed ID: 26366626
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of hydroxyurea on growth in children with sickle cell anemia: results of the HUG-KIDS Study.
    Wang WC; Helms RW; Lynn HS; Redding-Lallinger R; Gee BE; Ohene-Frempong K; Smith-Whitley K; Waclawiw MA; Vichinsky EP; Styles LA; Ware RE; Kinney TR
    J Pediatr; 2002 Feb; 140(2):225-9. PubMed ID: 11865275
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implementation of near-universal hydroxyurea uptake among children with sickle cell anemia: A single-center experience.
    Karkoska K; Todd K; Niss O; Clapp K; Fenchel L; Kalfa TA; Malik P; Quinn CT; Ware RE; McGann PT
    Pediatr Blood Cancer; 2021 Jun; 68(6):e29008. PubMed ID: 33742510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [From Hemoglobin SS to SF: interest of hydroxyurea in the management of sickle cell disease in two Congolese children and review of the literature].
    Nkashama GM; Wakamb GK; Mulangu AM; Nkashama GM; Kupa BK; Numbi OL
    Pan Afr Med J; 2015; 21():124. PubMed ID: 26327961
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia.
    Wang WC; Wynn LW; Rogers ZR; Scott JP; Lane PA; Ware RE
    J Pediatr; 2001 Dec; 139(6):790-6. PubMed ID: 11743503
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Treatment with hydroxyurea has revolutionized the evolution of sickle cell disease ].
    Bartolucci P; de Montalembert M
    Rev Prat; 2014 Oct; 64(8):1127-8. PubMed ID: 25510141
    [No Abstract]   [Full Text] [Related]  

  • 16. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea.
    Nottage KA; Ware RE; Winter B; Smeltzer M; Wang WC; Hankins JS; Dertinger SD; Shulkin B; Aygun B
    Eur J Haematol; 2014 Nov; 93(5):377-83. PubMed ID: 24796940
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hydroxyurea for sickle cell anemia.
    Naina HV; Harris S
    N Engl J Med; 2008 Jul; 359(1):98; author reply 98-9. PubMed ID: 18596283
    [No Abstract]   [Full Text] [Related]  

  • 18. Hydroxycarbamide use in young children with sickle-cell anaemia.
    Takahashi Y; Mori J; Tsubokura M; Matsumura T; Kami M
    Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098851
    [No Abstract]   [Full Text] [Related]  

  • 19. Hydroxycarbamide use in young children with sickle-cell anaemia.
    Obaro SK; Inusa B; Telfer P
    Lancet; 2011 Nov; 378(9805):1777. PubMed ID: 22098850
    [No Abstract]   [Full Text] [Related]  

  • 20. Treatment adherence in patients with sickle cell anemia.
    Drotar D
    J Pediatr; 2010 Mar; 156(3):350-1. PubMed ID: 20056235
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.